Αρχική World News PICOS Score May Help in Identification of Patients with Brain Metastasis at...

PICOS Score May Help in Identification of Patients with Brain Metastasis at High Risk for VTEs

In a large series of patients with brain metastasis, venous thromboembolic events (VTEs) were found in 12% of cases. The study team identified thrombogenicity of primary tumour, immobilisation, chemotherapy, obesity, and steroid use that are factors independently associated with VTEs and making components of the PICOS score. Fabian Wolpert of the Department of Neurology, University Hospital Zuirich in Zurich, Switzerland and colleagues reported in the European Journal of Cancer that the PICOS score is superior to established risk models for VTE risk estimation in cancer patients.

The study team reported in background that VTEs represent significant complications in patients with systemic malignancies. In patients with brain metastasis risk of thrombosis is poorly defined. Furthermore, available risk calculation scores are not validated in this population.

The authors identified 811 patients with brain metastasis. They retrospectively reviewed electronic charts for the occurrence of VTEs. Furthermore, they reviewed risk factors. Risk factors were tested in univariate and multivariate analyses and finally integrated in a score model for risk estimation. For validation phase, an independent cohort of 346 patients with brain metastasis was available.

From 811 patients included in the analysis, VTEs were documented in 97 patients (12.0%). The study team confirmed that next parameters are independently associated with VTEs: primary tumours with high thrombogenicity (p = 0.02, hazard ratio [HR] 1.7, 95% confidence interval [CI] 1.1–2.8), dexamethasone (p = 0.011, HR 2.27, 95% CI 1.5–4.5), chemotherapy (p = 0.005, HR 3.4, 95% CI 1.6–7.5), body mass index > 35 kg/m 2 (p = 0.002, HR 3.4, 95% CI 1.6–7.5) and immobilisation (p = 0.003, HR 2.4, 95% CI 1.3–4.3).

The authors derived a score model for VTE risk estimation called PICOS which is based on the thrombogenicity of primary tumour, immobilisation, chemotherapy, obesity, steroid use with possible score of 0 to 7 points.

They ran receiver-operating characteristic curve analysis which demonstrated its prognostic accuracy (area under the curve [AUC] 0.71, 95% CI 0.64–0.77). Its value for the evaluation of VTE risk was superior to that of other scores such as the Khorana (AUC 0.51) or CONKO (AUC 0.52) scores. The potential value of the PICOS score was confirmed in the validation cohort (AUC 0.72, 95% CI 0.63–0.82).

The authors concluded that the PICOS score may become a helpful tool to identify patients with brain metastasis who are at high risk for VTEs. It may be useful for stratification in controlled studies.

Reference

Wolpert F, Berghoff AS, Grossenbacher B, et al. Venous thromboembolic events in patients with brain metastases: the PICOS score. European Journal of Cancer 2020; 134:P75-85. DOI: https://doi.org/10.1016/j.ejca.2020.04.018

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

EMA Recommends Granting a Conditional Marketing Authorisation for Autologous Anti-CD19-Transduced CD3+ Cells

On 15 October 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...

New Treatment Helps Survivors Regain Sensation After Breast Cancer

When NBC’s Kristen Dahlgren was diagnosed with breast cancer, she didn’t think much about the lack of sensation that her mastectomy would likely leave...

Is there a future without Pap testing?

Maybe you saw the hashtag #DonutTakePAPAway on social media recently? ObGyn physicians and advocates are voicing their disagreement with the American Cancer Society’s (ACS)...

Mother Spent 14 Weeks Battling Breast Cancer Alone During COVID-19 Lockdown

Battling cancer is difficult for anyone, but it’s even harder when you have to do it alone. That’s what happened to Samantha Currie. Samantha, 27,...

ESMO 2020: New Treatments for Advanced Kidney Cancer, Prostate Cancer, and Bladder Cancer

The 2020 European Society for Medical Oncology (ESMO) Virtual Congress was held online from September 19 to September 21. In this podcast, Neeraj Agarwal,...

The UK Government’s spending review: Time to invest in the future of cancer care

This autumn, the chancellor Rishi Sunak will go to Parliament and set out the UK Government’s spending priorities in the Comprehensive Spending Review...